These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1555965)

  • 1. Some treatment planning considerations for 103Pd and 125I permanent interstitial implants.
    Nath R; Meigooni AS; Melillo A
    Int J Radiat Oncol Biol Phys; 1992; 22(5):1131-8. PubMed ID: 1555965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
    Yue N; Chen Z; Nath R
    Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of edema on planning 125I and 103Pd prostate implants.
    Yue N; Dicker AP; Nath R; Waterman FM
    Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
    Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
    Meigooni AS; Luerman CM; Sowards KT
    Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nomograph for permanent implants of palladium-103 seeds.
    Anderson LL; Moni JV; Harrison LB
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):129-35. PubMed ID: 8365933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
    Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
    Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
    Bohm TD; DeLuca PM; DeWerd LA
    Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of radial dose functions for 103Pd, 125I, 145Sm, 241Am, 169Yb, 192Ir, and 137Cs brachytherapy sources.
    Meigooni AS; Nath R
    Int J Radiat Oncol Biol Phys; 1992; 22(5):1125-30. PubMed ID: 1555964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
    Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
    Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
    Chibani O; Williamson JF; Todor D
    Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
    Butler WM; Merrick GS; Dorsey AT; Lief JH
    Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd.
    Lindsay P; Battista J; Van Dyk J
    Med Phys; 2001 Mar; 28(3):336-45. PubMed ID: 11318315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
    Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
    Li XA; Wang JZ; Stewart RD; DiBiase SJ
    Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
    Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
    Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seed fixity in the prostate/periprostatic region following brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Lief JH; Benson ML
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):215-20. PubMed ID: 10656395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.